Pfizer told pharmacies and clinics this week it will soon price a five-day course of COVID-19 treatment Paxlovid at almost $1,400, more than two-and-a-half times what the federal government has paid ...

Chiefs tight end Travis Kelce in commercial for Pfizer. Chiefs tight end Travis Kelce showed off two special rings for his latest commercial. Alas, they were not his Super Bowl championship rings, ...

Pfizer (NYSE:PFE) ran its first Super Bowl ad on Sunday, highlighting its efforts in oncology as the COVID-19 vaccine maker looks for post-pandemic growth following its recent acquisition of cancer ...

Aaron Rodgers is taking shots at Travis Kelce after the quarterback’s own controversy surrounding the COVID-19 vaccine. Rodgers, 39 — who is out for the rest of the 2023 season due to an Achilles ...

Pfizer brand teams competed in an internal shark-tank style challenge, and the winning teams received funding for their ideas. Out of roughly 100 ideas, 10 were pitched directly to a committee of ...

Dr. Marty Makary discusses the rebound rate after taking Paxlovid, the coronavirus-fighting drug touted by the White House, and how it's driving mutations at the population level on "The Ingraham ...

Pfizer’s (NYSE:PFE) COVID-19 drug Paxlovid will reportedly be priced at $1,390 per five day course when it becomes commercially available later this year, a steep increase from the $529 the drugmaker ...

Pfizer will no longer fund continuing medical education through med ed firms. The company, until recently the leading supporter of CME, said it will continue to support CME programs provided by ...

BARCELONA—Positive new colorectal cancer data has Pfizer envisioning a launch for its newly acquired Array BioPharma meds. And the company is getting prepared. Monday at the European Society for ...

Nearly 2 years after the company helped to develop the Covid vaccine, Pfizer's Angela Hwang said it's time to get back to the office. Though many worked from home during the vaccine's development, ...

Pfizer pulled the plug on the development of a cholesterol-lowering drug called bococizumab, citing a lack of commercial potential, reports Bloomberg Gadfly. Pfizer said the decision was partly fueled ...